Immungenetics AG is a clinical-stage biopharmaceutical company, developing effective treatments for neurodegenerative diseases. Current focus is on the diagnosis and treatment of Alzheimer's Disease.
The company was founded in 2009 and has obtained ISO 9001 certifications. Furthermore, the company is approved/listed to participate in major programmes such as ECAS, NATO, EMA, and USA/NIH.